A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study

Trial Profile

A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Canagliflozin (Primary) ; Gliclazide; Glimepiride; Pioglitazone; Repaglinide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms Can Do Ramadan
  • Sponsors Janssen Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 10 May 2016 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top